The move is part of the company’s plan to issue $21 billion of equity and $21 billion in fixed-income instruments over the next three years.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) said on Friday that it has entered into a securities purchase agreement with investor David Lazar, pursuant to which he agreed to purchase from the company 1M ...

Cyclacel Pharmaceuticals (CYCC) announced that the Company entered into a securities purchase agreement with investor David Lazar, pursuant to ...

Highlights,Convertible preferred stock allows holders to convert shares into common stock.,It combines the benefits of ...

HNO International, Inc. (OTC Pink: HNOI) (the "Company"), a leader in hydrogen-based clean energy technologies, announces a ...

Enhances Opportunity to Increase Shareholder Value Significantly Strengthens Balance Sheet Expands Regional Board with the ...

Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday's session. The company announced a securities purchase agreement with investor David Lazar.

Read here for an update on new investment opportunities in preferred stock and exchange traded debt offerings with yields ...

MicroStrategy (MSTR), in furtherance of its previously announced 21/21 Plan, a capital plan to raise $21 billion of equity and $21 billion of ...

Calamos Dynamic Convertible and Income Fund offers a high-yield and strong performance, but caution advised due to ...

MicroStrategy seeks $2 billion stock offering to bolster Bitcoin investments, part of its '21/21 Plan' targeting equity and ...